Reandron in Diabetic Men Witn Low Testosterone Level
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00613782|
Recruitment Status : Completed
First Posted : February 13, 2008
Last Update Posted : July 1, 2014
In men with type 2 diabetes, low testosterone levels have been associated with insulin resistance, truncal obesity and symptoms such as fatigue and erectile dysfunction. Low testosterone may impair cardiac function and increase cardiovascular risk and cause osteoporosis. The goal of this project is to assess prospectively whether, in men with type 2 diabetes mellitus and low testosterone levels, testosterone replacement improves insulin resistance, body composition, bone density, cardiac function symptoms associated with low testosterone level.
The investigators will recruit 140 ambulatory men with type 2 diabetes and a low serum testosterone level (<10 nmol/L) from Austin Health Endocrine clinics, General Practise surgeries, and from the general public by direct consumer advertising via newspaper and other local media. Men will be randomised to either intramuscular testosterone undecanoate (Reandron 1000, Bayer Schering Pharma) or placebo. Men with contraindications to testosterone replacement or to intramuscular injections will be excluded from the study. All men will receive intramuscular testosterone or placebo injections at 0, 6, 18 and 30 weeks (a total of four injections).
All 140 study subjects will have a clinical and laboratory assessment at baseline, 18 weeks and at study end (40 weeks). All 140 subjects will also have imaging studies at baseline and at study end (40 weeks). The study protocol is outlined in more detail below:
Clinical and laboratory assessment (Baseline and repeated 18 weeks, 40 weeks) A full medical history and physical examination will be performed. Symptoms will be assessed by the following standardised questionnaires: 1) Androgen Deficiency in the Aging Male (ADAM); 2) Aging Male Symptom scale (AMS); 3) International Index of Erectile Dysfunction (IIED); 4) International Prostate Symptom Score (IPSS); 5) SF-36 (all five questionnaires are attached to Module 1).
Laboratory studies will consist of blood tests to measure total testosterone, fasting glucose, C-peptide, HBA1c and other routine parameters.
Imaging studies (Baseline and repeated at 40 weeks)
- Body composition and bone mineral density by DEXA
- Body composition by magnetic resonance imaging
- Bony micro-architecture by high resolution quantitative computed tomography [HR-pQCT]),
- Cardiac dimensions and function by transthoracic doppler echocardiography
|Condition or disease||Intervention/treatment||Phase|
|Type 2 Diabetes Hypogonadism||Drug: Reandron 1000 Drug: placebo||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||88 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Testosterone Replacement Therapy in Men With Type 2 Diabetes Mellitus and Low Testosterone Levels|
|Study Start Date :||January 2009|
|Primary Completion Date :||January 2014|
|Study Completion Date :||April 2014|
Active Comparator: 1
Reandron 100 treatment
Drug: Reandron 1000
1000mg at 0,6,18,30 weeks
Other Name: testosterone undecanoate
Placebo Comparator: 2
placebo injection 0,6.18.30 weeks
- Insulin Resistance [ Time Frame: 40 weeks ]
- Bone microarchitecture [ Time Frame: 40 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00613782
|Melbourne, Victoria, Australia, 3084|
|Principal Investigator:||Mathis Grossmann||Austin Health|